The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Agomelatine in the Treatment of Major Depressive Disorder: An 8-Week, Multicenter, Randomized, Placebo-Controlled Trial
Abstract
OBJECTIVE: To evaluate the efficacy, safety, and tolerability of fixed-dose agomelatine 25 and 50 mg/d in the treatment of outpatients with moderate-to-severe major depressive disorder (MDD) compared to placebo. METHOD: In this 8-week, multicenter, double-blind, parallel-group trial, patients with DSM-IV-defined MDD were randomly assigned (1:1:1) to receive a once-daily dose of agomelatine 25 mg, agomelatine 50 mg, or placebo. The primary efficacy measure was the change from baseline to week 8 in the clinician-rated 17-item Hamilton Depression Rating Scale (HDRS(17)); other efficacy measures were the clinical remission and response rates (measured by HDRS(17)), Clinical Global Impressions scales, Hospital Anxiety and Depression Scale (HADS) score, subjective measures on sleep, and the overall quality of life. The study was conducted between December 2006 and January 2008. RESULTS: Agomelatine 25 mg/d was more efficacious based on the HDRS(17) total score (P = .01) compared to placebo throughout the treatment period, whereas for agomelatine 50 mg/d, statistically significant reduction in HDRS(17) total score could be observed from weeks 2 to 6 but not at week 8 (P = .144). A higher proportion of patients receiving agomelatine 25 mg/d showed clinical response (P = .013), clinical remission (P = .07), and improvement according to the Clinical Global Impressions-Improvement scale (P = .065) compared to those receiving placebo. No statistically significant difference between patients receiving agomelatine 50 mg/d compared to placebo on clinical response (P = .116) or clinical remission (P =. 457) was observed. HADS score, quality of sleep, and quality of life significantly improved with agomelatine 25 mg/d compared to placebo. Both agomelatine doses were safe and well tolerated, although clinically notable aminotransferase elevations were observed transiently in the agomelatine 50 mg/d group. CONCLUSIONS: Agomelatine 25 mg/d was effective in the treatment of patients with moderate-to-severe MDD and was safe and well tolerated. Agomelatine 50 mg/d provided evidence for its antidepressant efficacy until week 6 and was also safe and well tolerated. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00411242.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
(1976) · Medical Entomology and Zoology · Cited by 8,899
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Higgins, S. M. F., Macken, A. P., Cullen, W., Saunders, J., Dunne, C. P., & O’Gorman, C. S. (2013) · PubMed · doi:10.34961/9953 · Cited by 4,806
Yatham, L., & Malhi, G. (2011) · Oxford University Press eBooks · doi:10.1093/med/9780199562305.001.0001 · Cited by 3,506
Belmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
Circadian rhythm disturbances in depression
Germain, A., & Kupfer, D. J. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.964 · Cited by 644
Stahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 458
Self-citationL??o, H., Hale, A., & D??haenen, H. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00004 · Cited by 361
Biological rhythm disturbances in mood disorders
Wirz-Justice, A. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000195660.37267.cf · Cited by 354
Dysregulation of Endogenous Opioid Emotion Regulation Circuitry in Major Depression in Women
Kennedy, S. E., Koeppe, R. A., Young, E. A., & Zubieta, J.-K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1199 · Cited by 338
The QLDS: A scale for the measurement of quality of life in depression
Hunt, S. M., & McKenna, S. P. (1992) · Health Policy · doi:10.1016/0168-8510(92)90004-u · Cited by 314
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
Kennedy, S. H., & Emsley, R. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.09.002 · Cited by 294
Handling drop‐out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches
Lane, P. (2008) · Pharmaceutical Statistics · doi:10.1002/pst.267 · Cited by 262
Pierre Olié, J., & Kasper, S. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007766 · Cited by 256
Daytime sleepiness and insomnia as correlates of depression.
D, M. F. M. (2004) · PubMed · Cited by 245
Gartlehner, G., Gaynes, B. N., Hansen, R. A., Thieda, P., DeVeaugh-Geiss, A., Krebs, E. E., Moore, C. G., Morgan, L., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00008 · Cited by 237
Epidemiology of specific phobia subtypes: findings from the Dresden Mental Health Study
Becker, E. S., Rinck, M., Türke, V., Kause, P., Goodwin, R., Neumer, S., & Margraf, J. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2006.09.006 · Cited by 224
Lemoine, P., & Guilleminault, C. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1112 · Cited by 217
Major depressive disorder, sleep EEG and agomelatine: an open-label study
Salva, M.-A. Q., Vanier, B., Laredo, J., Hartley, S., Chapotot, F., Moulin, C., Lofaso, F., & Guilleminault, C. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007754 · Cited by 170
Agomelatine: A Preliminary Review of a New Antidepressant
Zupancic, M. J., & Guilleminault, C. (2006) · CNS Drugs · doi:10.2165/00023210-200620120-00003 · Cited by 155
Clinical issues in long-term treatment with antidepressants.
Zajecka, J. M. (2000) · PubMed · Cited by 144
Quality of life in bipolar disorder patients: a comparison with a general population sample
Gutiérrez‐Rojas, L., Gurpegui, M., Ayuso‐Mateos, J. L., Gutiérrez‐Ariza, J. A., Ruiz‐Veguilla, M., & Jurado, D. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2008.00604.x · Cited by 137
San, L., & Arranz, B. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.04.002 · Cited by 135
Circadian abnormalities, molecular clock genes and chronobiological treatments in depression
Bunney, J., & Potkin, S. G. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldn019 · Cited by 131
Agomelatine in the treatment of seasonal affective disorder
Pjrek, E., Winkler, D., Konstantinidis, A., Willeit, M., Praschak-Rieder, N., & Kasper, S. F. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0645-3 · Cited by 117
Melander, H., Salmonson, T., Abadie, E., & van Zwieten-Boot, B. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.06.003 · Cited by 117
Antidepressant action of agomelatine (S 20098) in a transgenic mouse model
Barden, N., Shink, É., Labbé, M., Vacher, R., Rochford, J. M., & Mocaër, E. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.04.032 · Cited by 102
Onset of action of antidepressants: results of different analyses
Thompson, C. (2002) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.386 · Cited by 92
Efficacy and tolerance profile of agomelatine and practical use in depressed patients
Rouillon, F. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000195659.99148.09 · Cited by 72
Hanoun, N., Mocaër, E., Boyer, P., Hamon, M., & Lanfumey, L. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.06.003 · Cited by 71
Bipolar Depression in a Low-Income Primary Care Clinic
Olfson, M., Das, A. K., Gameroff, M. J., Pilowsky, D. J., Feder, A., Gross, R., Lantigua, R., Shea, S. A., & Weissman, M. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.2146 · Cited by 69
Relapse and Recurrence of Depression: A Practical Approach for Prevention
Thase, M. E., & Sullivan, L. R. (1995) · CNS Drugs · doi:10.2165/00023210-199504040-00004 · Cited by 61
Held, K., Antonijevic, I. A., Murck, H., Kuenzel, H., & Steiger, A. (2005) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.05.015 · Cited by 58
Clinical efficacy of agomelatine in depression: the evidence
den Boer, J. A., Bosker, F. J., & Meesters, Y. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000195661.37267.86 · Cited by 57
Onset of action of antidepressants
Tylee, A. T., & Walters, P. (2007) · BMJ · doi:10.1136/bmj.39197.619190.80 · Cited by 43
Stahl, S. M. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008000 · Cited by 31
Self-citationQuality of life of Turkish patients with depression in Ankara and in Berlin
Akbıyık, D. İ., Berksun, O. E., Sümbüloğlu, V., Şentürk, V., & Priebe, S. (2008) · European Psychiatry · doi:10.1016/s0924-9338(08)70055-5 · Cited by 23
Eşel, E., Kartalcı, Ş., Tutuş, A., Turan, T., & Sofuoǧlu, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.10.009 · Cited by 12
Cited by
Major depressive disorder: new clinical, neurobiological, and treatment perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60602-8 · Cited by 894
Novel melatonin-based therapies: potential advances in the treatment of major depression
Hickie, I. B., & Rogers, N. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60095-0 · Cited by 334
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
Taylor, D., Sparshatt, A., Varma, S., & Olofinjana, O. (2014) · BMJ · doi:10.1136/bmj.g1888 · Cited by 334
Role of melatonin in mood disorders and the antidepressant effects of agomelatine
Srinivasan, V., De Berardis, D., Shillcutt, S. D., & Brzezinski, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.711314 · Cited by 84
Neuroscience-driven discovery and development of sleep therapeutics
Dresler, M., Spoormaker, V. I., Beitinger, P., Czisch, M., Kimura, M., Steiger, A., & Holsboer, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.012 · Cited by 63
Metadata
- Authors
- Stahl, S. M., Fava, M., Trivedi, M. H., Caputo, A., Shah, A., & Post, A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-03-23
- Volume
- 71
- Issue
- 05
- Pages
- 616-626
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2045614420
- Cited by
- 262
- References
- 42
- FWCI
- 11.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.